We are happy announce that the 2017 Research Models and Services Catalog has been transitioned to a fully digital platform, supporting our mission to go green.
Whole-exome sequencing (WES) results from our syngeneic models are now available globally to help in appropriate model selection.
Regulatory authorities are increasingly focused on this area and have specific guidelines outlining procedures and qualifications that should be performed when evaluating the efficacy of disinfectants in sterile facilities.
Now offering in vitro aerosol product testing using the VITROCELL VC 10® robot.
Our scientists present new and improving techniques for analyzing heavy metals and elements through inductively coupled plasma.
Comprehensive preclinical assessment of stem cell therapies is critical for regulatory approval and to ensure safety in first-in-human clinical trials. Here are some tips to consider for a successful translational cell therapy program.
Agilux’s unique combination of early-stage services, coupled with our existing discovery and safety assessment capabilities, will greatly enhance the speed and efficiency of your lead identification, optimization and candidate selection.
Our latest paper, featured on the cover of ASSAY and Drug Development Technologies, discusses the development and validation of high-throughput screens for human nicotinic receptor subtypes in automated patch-clamp.
Charles River is now able to offer CTLA4 and PD-1/PD-L1 reporter bioassays, along with a bioassay for human growth hormone (HGH).
Our partnership with PathoQuest will now provide an NGS-based testing solution, which can identify viral contaminants in biological products via a single comprehensive test.